Latest news with #CellSignalingTechnology
Yahoo
27-05-2025
- Business
- Yahoo
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck
The Saudi Arabia research antibodies market, valued at USD 10.52 Million in 2024, is projected to reach USD 12.71 Million by 2030, growing at a CAGR of 3.40%. This growth is fueled by expanding life sciences and R&D investments. Key challenges include high costs and reliance on imports. Custom antibody services and advances in personalized medicine are emerging trends. Major players like Cell Signaling Technology and Becton, Dickinson and Company dominate the market. The report covers technology and application insights and offers customization options for company-specific data. Saudi Arabian Research Antibodies Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Research Antibodies Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Research Antibodies Market, valued at USD 10.52 Million in 2024, is projected to grow to USD 12.71 Million by 2030, reflecting a CAGR of 3.40%. This growth trajectory is fueled by the expansion of the life sciences sector, increased R&D investments, and a heightened focus on biomedical research across the Kingdom. Research antibodies, essential tools in molecular biology, immunology, and biochemistry, are becoming vitally important for detecting, analyzing, and quantifying proteins and biological molecules. As Saudi Arabia aims to become a leader in biotechnology under its Vision 2030 initiative, the demand for high-quality research antibodies is set to rise. Local and international suppliers are increasingly catering to the needs of the country's burgeoning research community. Nevertheless, challenges such as the limited availability of domestically produced antibodies persist, leading to a dependency on imports. Key Market Drivers The growth of Saudi Arabia's healthcare industry significantly drives the research antibodies market. As healthcare infrastructure expands, driven by Vision 2030, the demand for advanced research tools like antibodies has increased. These antibodies are crucial for medical research and diagnostics, allowing for in-depth disease studies, treatment development, and improved diagnostic accuracy. A significant factor propelling market growth is the focus on disease prevention and personalized medicine. In January 2025, King Faisal Specialist Hospital & Research Center announced updates to its Biobank Center, marking a pivotal advancement in healthcare and medical research aligned with the objectives of Saudi Vision 2030. Key Market Challenges Expensive antibody costs pose challenges in the market, especially for specialized applications. The complexity involved in developing, producing, and controlling the quality of these antibodies results in high costs, impacting research budgets of academic institutions and biotech companies. Additionally, reliance on imported antibodies increases costs due to shipping, import taxes, and currency fluctuations, making cutting-edge research tools less accessible. Key Market Trends Custom antibody services have emerged as a significant trend, catering to the need for highly specific antibodies tailored for various research projects and diagnostic applications. This trend is driven by Saudi Arabia's increasingly complex research landscape, particularly in fields like personalized medicine, drug development, and precision diagnostics. Companies like GenScript offer comprehensive custom polyclonal antibody production services, ensuring quality and quick turnaround times, which are crucial for advancing medical research and diagnostics. Report Scope Key Market Players Cell Signaling Technology, Inc. Salima Trading Corp. AJ Jeel Medical & Trading Co. Ltd. Becton, Dickinson and Company Merck Limited Saudi Arabia Research Antibodies Market, By Technology: Immunohistochemistry Immunofluorescence Western blotting Flow cytometry Immunoprecipitation ELISA Others Saudi Arabia Research Antibodies Market, By Application: Infectious Diseases Immunology Oncology Stem Cells Neurobiology Others Saudi Arabia Research Antibodies Market, By Region: Eastern Western Northern & Central Southern Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.52 Million Forecasted Market Value (USD) by 2030 $12.71 Million Compound Annual Growth Rate 3.4% Regions Covered Saudi Arabia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Research Antibodies Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Yahoo
27-05-2025
- Business
- Yahoo
Saudi Arabia Research Antibodies Market Report 2025-2030, Competitive Analysis of Cell Signaling Technology, Salima Trading, AJ Jeel Medical & Trading Co, Becton, Dickinson and Co, and Merck
The Saudi Arabia research antibodies market, valued at USD 10.52 Million in 2024, is projected to reach USD 12.71 Million by 2030, growing at a CAGR of 3.40%. This growth is fueled by expanding life sciences and R&D investments. Key challenges include high costs and reliance on imports. Custom antibody services and advances in personalized medicine are emerging trends. Major players like Cell Signaling Technology and Becton, Dickinson and Company dominate the market. The report covers technology and application insights and offers customization options for company-specific data. Saudi Arabian Research Antibodies Market Dublin, May 27, 2025 (GLOBE NEWSWIRE) -- The "Saudi Arabia Research Antibodies Market, By Region, Competition, Forecast & Opportunities, 2020-2030F" has been added to offering. The Saudi Arabia Research Antibodies Market, valued at USD 10.52 Million in 2024, is projected to grow to USD 12.71 Million by 2030, reflecting a CAGR of 3.40%. This growth trajectory is fueled by the expansion of the life sciences sector, increased R&D investments, and a heightened focus on biomedical research across the Kingdom. Research antibodies, essential tools in molecular biology, immunology, and biochemistry, are becoming vitally important for detecting, analyzing, and quantifying proteins and biological molecules. As Saudi Arabia aims to become a leader in biotechnology under its Vision 2030 initiative, the demand for high-quality research antibodies is set to rise. Local and international suppliers are increasingly catering to the needs of the country's burgeoning research community. Nevertheless, challenges such as the limited availability of domestically produced antibodies persist, leading to a dependency on imports. Key Market Drivers The growth of Saudi Arabia's healthcare industry significantly drives the research antibodies market. As healthcare infrastructure expands, driven by Vision 2030, the demand for advanced research tools like antibodies has increased. These antibodies are crucial for medical research and diagnostics, allowing for in-depth disease studies, treatment development, and improved diagnostic accuracy. A significant factor propelling market growth is the focus on disease prevention and personalized medicine. In January 2025, King Faisal Specialist Hospital & Research Center announced updates to its Biobank Center, marking a pivotal advancement in healthcare and medical research aligned with the objectives of Saudi Vision 2030. Key Market Challenges Expensive antibody costs pose challenges in the market, especially for specialized applications. The complexity involved in developing, producing, and controlling the quality of these antibodies results in high costs, impacting research budgets of academic institutions and biotech companies. Additionally, reliance on imported antibodies increases costs due to shipping, import taxes, and currency fluctuations, making cutting-edge research tools less accessible. Key Market Trends Custom antibody services have emerged as a significant trend, catering to the need for highly specific antibodies tailored for various research projects and diagnostic applications. This trend is driven by Saudi Arabia's increasingly complex research landscape, particularly in fields like personalized medicine, drug development, and precision diagnostics. Companies like GenScript offer comprehensive custom polyclonal antibody production services, ensuring quality and quick turnaround times, which are crucial for advancing medical research and diagnostics. Report Scope Key Market Players Cell Signaling Technology, Inc. Salima Trading Corp. AJ Jeel Medical & Trading Co. Ltd. Becton, Dickinson and Company Merck Limited Saudi Arabia Research Antibodies Market, By Technology: Immunohistochemistry Immunofluorescence Western blotting Flow cytometry Immunoprecipitation ELISA Others Saudi Arabia Research Antibodies Market, By Application: Infectious Diseases Immunology Oncology Stem Cells Neurobiology Others Saudi Arabia Research Antibodies Market, By Region: Eastern Western Northern & Central Southern Key Attributes: Report Attribute Details No. of Pages 85 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $10.52 Million Forecasted Market Value (USD) by 2030 $12.71 Million Compound Annual Growth Rate 3.4% Regions Covered Saudi Arabia For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Saudi Arabian Research Antibodies Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Associated Press
25-03-2025
- Business
- Associated Press
Leveragen Partners with Cell Signaling Technology to Advance Reagent Antibody Innovation with Proprietary Nanobody Technology
Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling Technology (CST), a global leader in high-quality research antibodies and associated reagents. This collaboration will explore Leveragen's proprietary Singularity Musculus platform to expedite the development of mouse-derived nanobodies tailored for reagent antibody applications. This press release features multimedia. View the full release here: Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling Technology (CST), a global leader in high-quality research antibodies and associated reagents. This collaboration will explore Leveragen's proprietary Singularity Musculus platform to expedite the development of mouse-derived nanobodies tailored for reagent antibody applications. Nanobodies, or single-domain antibodies, are only about 10% the size of traditional antibodies, yet retain high target-binding affinity, exhibit enhanced tissue penetration, and can tackle structurally-challenging targets inaccessible to some full-length antibodies. Leveragen's Singularity Suite of nanobody mice harnesses cutting-edge genetic engineering technologies to remove competing conventional antibodies and preserve native immunoglobulin gene regulation, maximizing nanobody-specific immune responses and maintaining normal B-cell development. Similar to its flagship Singularity Sapiens platform of fully human single-domain antibodies developed for therapeutic applications, the Singularity Musculus platform is purpose-built to generate mouse-derived nanobodies with superior diversity, affinity, stability, and cost-efficiency—traits critical to developing high-performance reagents for research and diagnostic applications. 'We are excited to begin this partnership with CST, marking a major milestone that underscores our commitment to antibody innovation,' said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen Inc. 'Our Singularity Musculus platform was developed specifically to meet the growing need for versatile, diverse, and reproducible reagent antibodies. By merging our proprietary Singularity Musculus platform with CST's renowned expertise in antibody reagents, we aim to raise the bar for nanobody-based tools throughout the life sciences.' Dr. Roberto Polakiewicz, Chief Scientific Officer at Cell Signaling Technology, commented, 'We are delighted to collaborate with Leveragen to explore the Singularity Musculus platform and its potential to advance reagent antibody development for researchers around the world.' This partnership highlights the growing significance of nanobody-based technologies in areas including basic research, diagnostics, and therapeutic development. With their small molecular footprint, modular monomeric structure, robust binding affinity, and suitability for certain challenging antigens, nanobodies are uniquely positioned for high-throughput screening, precision imaging, and other advanced life science applications. By combining Leveragen's and CST's expertise, the collaboration aims to accelerate the creation of next-generation reagent antibodies. About Leveragen Leveragen is a genetic engineering company dedicated to transforming antibody discovery and development for research, diagnostics, and therapeutics. Operating exclusively from its Woburn, Massachusetts facility, the company employs advanced genome editing, synthetic biology, and chromosomal engineering technologies to develop next-generation genetic models that accelerate antibody discovery. Leveragen's proprietary collection of nanobody mice, the Singularity Suite, features Singularity Sapiens, designed to generate fully human single-domain antibodies for developing a broad range of biologic modalities, and Singularity Musculus, engineered to produce mouse-derived single-domain antibodies optimized for high-performance reagent applications. Through strategic collaborations with global pharmaceutical and biotechnology leaders, the company addresses unmet medical needs and accelerates the translation of scientific breakthroughs into practical solutions. For more information, please visit About Cell Signaling Technology Cell Signaling Technology (CST), headquartered in Danvers, Massachusetts, is a global leader in the development and production of high-quality research antibodies, reagents, and related technologies. Established in 1999 by scientists committed to furthering cellular and molecular research, CST has earned a reputation for excellence through rigorous validation processes, innovative products, and dedication to reproducibility. Serving academia, pharmaceuticals, and biotechnology worldwide, CST provides tools that help researchers investigate complex signaling pathways, uncover disease mechanisms, and accelerate therapeutic discovery. With a focus on quality and customer service, CST remains at the cutting edge of life science innovation. Learn more at SOURCE: Leveragen Inc. Copyright Business Wire 2025. PUB: 03/25/2025 08:08 AM/DISC: 03/25/2025 08:08 AM
Yahoo
25-03-2025
- Business
- Yahoo
Leveragen Partners with Cell Signaling Technology to Advance Reagent Antibody Innovation with Proprietary Nanobody Technology
BOSTON, March 25, 2025--(BUSINESS WIRE)--Leveragen Inc., a Boston-based biotechnology company specializing in next-generation genetic models for antibody discovery, today announced a comprehensive collaboration with Cell Signaling Technology (CST), a global leader in high-quality research antibodies and associated reagents. This collaboration will explore Leveragen's proprietary Singularity Musculus platform to expedite the development of mouse-derived nanobodies tailored for reagent antibody applications. Nanobodies, or single-domain antibodies, are only about 10% the size of traditional antibodies, yet retain high target-binding affinity, exhibit enhanced tissue penetration, and can tackle structurally-challenging targets inaccessible to some full-length antibodies. Leveragen's Singularity Suite of nanobody mice harnesses cutting-edge genetic engineering technologies to remove competing conventional antibodies and preserve native immunoglobulin gene regulation, maximizing nanobody-specific immune responses and maintaining normal B-cell development. Similar to its flagship Singularity Sapiens platform of fully human single-domain antibodies developed for therapeutic applications, the Singularity Musculus platform is purpose-built to generate mouse-derived nanobodies with superior diversity, affinity, stability, and cost-efficiency—traits critical to developing high-performance reagents for research and diagnostic applications. "We are excited to begin this partnership with CST, marking a major milestone that underscores our commitment to antibody innovation," said Dr. Weisheng Chen, Founder and Chief Executive Officer of Leveragen Inc. "Our Singularity Musculus platform was developed specifically to meet the growing need for versatile, diverse, and reproducible reagent antibodies. By merging our proprietary Singularity Musculus platform with CST's renowned expertise in antibody reagents, we aim to raise the bar for nanobody-based tools throughout the life sciences." Dr. Roberto Polakiewicz, Chief Scientific Officer at Cell Signaling Technology, commented, "We are delighted to collaborate with Leveragen to explore the Singularity Musculus platform and its potential to advance reagent antibody development for researchers around the world." This partnership highlights the growing significance of nanobody-based technologies in areas including basic research, diagnostics, and therapeutic development. With their small molecular footprint, modular monomeric structure, robust binding affinity, and suitability for certain challenging antigens, nanobodies are uniquely positioned for high-throughput screening, precision imaging, and other advanced life science applications. By combining Leveragen's and CST's expertise, the collaboration aims to accelerate the creation of next-generation reagent antibodies. About Leveragen Leveragen is a genetic engineering company dedicated to transforming antibody discovery and development for research, diagnostics, and therapeutics. Operating exclusively from its Woburn, Massachusetts facility, the company employs advanced genome editing, synthetic biology, and chromosomal engineering technologies to develop next-generation genetic models that accelerate antibody discovery. Leveragen's proprietary collection of nanobody mice, the Singularity Suite, features Singularity Sapiens, designed to generate fully human single-domain antibodies for developing a broad range of biologic modalities, and Singularity Musculus, engineered to produce mouse-derived single-domain antibodies optimized for high-performance reagent applications. Through strategic collaborations with global pharmaceutical and biotechnology leaders, the company addresses unmet medical needs and accelerates the translation of scientific breakthroughs into practical solutions. For more information, please visit About Cell Signaling Technology Cell Signaling Technology (CST), headquartered in Danvers, Massachusetts, is a global leader in the development and production of high-quality research antibodies, reagents, and related technologies. Established in 1999 by scientists committed to furthering cellular and molecular research, CST has earned a reputation for excellence through rigorous validation processes, innovative products, and dedication to reproducibility. Serving academia, pharmaceuticals, and biotechnology worldwide, CST provides tools that help researchers investigate complex signaling pathways, uncover disease mechanisms, and accelerate therapeutic discovery. With a focus on quality and customer service, CST remains at the cutting edge of life science innovation. Learn more at View source version on Contacts Media Contact Leveragen Media RelationsEmail: media@ Sign in to access your portfolio
